May 8, 2020
Ocular Therapeutix CEO: outlook continues to brighten
First Quarter DEXTENZA® Net Product Revenue of $2.1 million, a 31% Sequential Increase Compared with Fourth Quarter of 2019
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
May 8, 2020
HighTide Phase 2 in primary sclerosing cholangitis in the U.S., Canada, topline results expected in 2H2020
HighTide is expecting to finalize the data analysis and is preparing submissions for presentation and peer-reviewed publication.
May 8, 2020
EC OK Entyvio formulation as maintenance therapy in adult patients with UC or CD
Takeda’s approval makes Entyvio the only maintenance therapy approved across Europe with both intravenous and subcutaneous formulation options for adult patients with ulcerative colitis or Crohn’s disease.
May 7, 2020
NIH-Sponsored COVID-19 testing kicks off at Lundquist institute
Researchers at The Lundquist Institute began Thursday a randomized, double-blind, placebo-controlled clinical trial designed to find out whether hydroxychloroquine and azithromycin reduce hospitalization and/or death in individuals suffering from COVID-19
May 7, 2020
Amid the COVID-19 Crisis, Clinical Research is Experiencing a Renaissance of Collaboration and Speed
Shifting financial markets prove the weight science and research carry in the current climate ATLANTA–(BUSINESS WIRE)–More than ever before, collaboration…
May 7, 2020
Columbia Care Reports Preliminary First Quarter 2020 Results and Provides Operational Update
Unaudited First Quarter Combined Revenue (1) up 125% Over Prior Year Period and 18% Sequentially Capital Transactions Provide Approximately $45…
May 7, 2020
Teva reports first quarter 2020 revenues of $4.4 billion
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended March 31, 2020, including revenues…
May 7, 2020
Scholar Rock Reports First Quarter 2020 Financial Results and Highlights Business Progress
– Progressing TOPAZ Phase 2 clinical trial of SRK-015 in patients with Spinal Muscular Atrophy; interim efficacy and safety results…
May 7, 2020
Tetraphase Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Developments
Entered into Definitive Merger Agreement with AcelRx Pharmaceuticals; Acquisition Expected to Close in June 2020 Continued double digit quarter over…
May 7, 2020
ZYUS Collaborates with USask’s VIDO-InterVac to Develop a Plant-Based Vaccine for COVID-19
ZYUS Life Sciences to support research and development of a vaccine for COVID-19 SASKATOON, Saskatchewan–(BUSINESS WIRE)–ZYUS Life Sciences Inc. (“ZYUS”),…